American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Alto Neuroscience, Inc. (ANRO)

$21.97 -1.04% NYSE: ANRO · 15-min delayed

MOUNTAIN VIEW, California
Public · NYSE: ANRO
68 employees

Visit website Follow

$1.0BMarket cap

-$63.2MNet income

68Employees

ANRONYSE

2024IPO

About Alto Neuroscience, Inc.

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NYSE: ANRO
Employees: 68
IPO date: Feb 2, 2024
Headquarters: 650 CASTRO STREET, SUITE 450
MOUNTAIN VIEW, California 94041
Phone: 773-255-5012
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: ANRO NYSE
SEC CIK: 1999480
LEI: 549300I1AHR8KMMFIS52
EIN: 834210124
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Alto Neuroscience, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/alto-neuroscience-inc/"><img src="https://americancompanies.com/badge/alto-neuroscience-inc.svg" alt="Alto Neuroscience, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Alto Neuroscience, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Net income: -$63.2M
Total assets: $184.7M
Market cap: $1.0B

Source: SEC EDGAR · updated Jun 7, 2026

NYSE: ANRO

$21.97 -1.04%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$3.80 $36.64

52-week range

Market cap: $1.0B
Shares outstanding: 47.4M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Feb 2, 2024

Alto Neuroscience, Inc. (ANRO) Stock Price

Reported a net loss of $63.2M.
Trading 40% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Alto Neuroscience, Inc..

Write a review

Newsroom

News about Alto Neuroscience, Inc.

Here's Why You Should Add ANRO Stock to Your Portfolio Now Zacks Investment Research · 2026-10-14 · positive Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders Benzinga · 2026-02-26 · positive ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm GlobeNewswire Inc. · 2025-10-07 · negative Investors who lost money on Alto Neuroscience, Inc.(ANRO) should contact Levi & Korsinsky about pending Class Action - ANRO GlobeNewswire Inc. · 2025-09-19 · negative ANRO DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO GlobeNewswire Inc. · 2025-09-19 · negative ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire Inc. · 2025-09-18 · negative

News & sentiment via Polygon.io

FAQ

Alto Neuroscience, Inc.: frequently asked questions

Is Alto Neuroscience, Inc. an American company?

Alto Neuroscience, Inc. is a US-based company headquartered in Mountain View, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Alto Neuroscience, Inc. headquartered?

Alto Neuroscience, Inc. is headquartered in Mountain View, California, United States.

Is Alto Neuroscience, Inc. publicly traded?

Yes — Alto Neuroscience, Inc. is a publicly traded company. Its stock trades under the ticker symbol ANRO on the NYSE.

What does Alto Neuroscience, Inc. do?

Alto Neuroscience, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore